prikaz prve stranice dokumenta Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty
  Preuzmi
PDF 3.37 MB
Znanstveni rad - Izvorni znanstveni rad
Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty
International Orthopaedics, 36 (2012), 4; 703-709. https://doi.org/10.1007/s00264-011-1367-7
Buljan, Melita; Nemet, Damir; Golubić-Ćepulić, Branka; Bićanić, Goran; Tripković, Branko; Delimar, Domagoj

Citirajte ovaj rad

Buljan, M., Nemet, D., Golubić Ćepulić, B., Bićanić, G., Tripković, B. i Delimar, D. (2012). Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. International Orthopaedics, 36. (4), 703-709. doi: 10.1007/s00264-011-1367-7

Buljan, Melita, et al. "Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty." International Orthopaedics, vol. 36, br. 4, 2012, str. 703-709. https://doi.org/10.1007/s00264-011-1367-7

Buljan, Melita, Damir Nemet, Branka Golubić Ćepulić, Goran Bićanić, Branko Tripković i Domagoj Delimar. "Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty." International Orthopaedics 36, br. 4 (2012): 703-709. https://doi.org/10.1007/s00264-011-1367-7

Buljan, M., et al. (2012) 'Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty', International Orthopaedics, 36(4), str. 703-709. doi: 10.1007/s00264-011-1367-7

Buljan M, Nemet D, Golubić Ćepulić B, Bićanić G, Tripković B, Delimar D. Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. International Orthopaedics [Internet]. 04.2012. [pristupljeno 27.04.2024.];36(4):703-709. doi: 10.1007/s00264-011-1367-7

M. Buljan, D. Nemet, B. Golubić Ćepulić, G. Bićanić, B. Tripković i D. Delimar, "Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty", International Orthopaedics, vol. 36, br. 4, str. 703-709, Travanj 2012. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:792126. [Citirano: 27.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:792126
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty
AutorMelita Buljan
AutorDamir Nemet
AutorBranka Golubić-Ćepulić
AutorGoran Bićanić
AutorBranko Tripković
AutorDomagoj Delimar
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
PURPOSE: Our aim was to evaluate the effectiveness of two different dosing regimens of human recombinant erythropoietin (rHu-EPO) for preoperative autologous blood collection in patients undergoing total hip arthroplasty (THA). ----- METHODS: Prospective randomised trials in which erythropoietin 15,000 IU was administered intravenously twice a week or 30,000 IU once a week (total 90,000 IU) combined with ferrous II sulphate (Ferro-Gradumet 2) orally and compared with Ferro-Gradumet 2 alone. ----- RESULTS: Although different dosing regimens of rHu-EPO administration during preoperative autologous blood donation have similar effects on the collection of two units of autologous blood, preoperative haemoglobin level and perioperative allogenic blood transfusion, a once weekly dose regimen of rHu-EPO was more convenient (although not statistically significantly) for patients. ----- CONCLUSION: We recommend the more practical and comfortable but yet highly effective therapeutic regimen with a single weekly intravenous administration of rHu-EPO for patients scheduled for THA.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaInternational Orthopaedics
Brojčani podacivol. 36, br. 4, str. 703-709
p-ISSN0341-2695
DOIhttps://doi.org/10.1007/s00264-011-1367-7
URN:NBNurn:nbn:hr:105:792126
Datum objave publikacije2012-04
URL dokumentahttps://doi.org/10.1007/s00264-011-1367-7
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-27 19:31:14